Castle (CSTL) Q2 Revenue Tops Estimates

Castle Biosciences (NASDAQ:CSTL), a developer of diagnostic tests supporting personalized treatment decisions in dermatology and gastroenterology, reported its second quarter 2025 results on August 4, 2025. The company significantly outperformed Wall Street expectations in Q2 2025, with GAAP EPS of $0.15 and non-GAAP revenue of $86.2 million, both exceeding analyst estimates. GAAP earnings per share reached $0.15, well above the consensus estimate of -$0.53. Non-GAAP revenue was $86.2 million, surpassing the anticipated $71.45 million. While Revenue was nearly flat year-over-year, with GAAP revenue of $86.2 million in Q2 2025 compared to $87.0 million in Q2 2024, and the company raised its full-year 2025 revenue guidance highlighting strong growth in core test volumes. Core revenue driver test reports increased 33% year-over-year in both Q1 and Q2 2025, though the definition of core revenue drivers differed between quarters. However, lower reimbursement for some products and A shrinking gross margin contributed to a mixed overall picture for the quarter. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Castle Biosciences is a molecular diagnostics company specializing in tests that provide physicians with actionable information for managing skin, gastrointestinal, and mental health diseases. Its business centers on developing and commercializing tests that guide decisions such as treatment selection and patient monitoring.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool